lilly glp-1 drug GLP Molecular Glue The FDA has approved a

Important conclusions drawn from recent meta-analyses involving over 300,000 patients report that while the retained gastric contents are significantly increased (fivefold to tenfold increase

This formula is convenient to use with just one capsule per serving

This is a huge market

I'm pleased to share that npj Metabolic Health and Disease is joining Communications Medicine on a new collection looking at the Therapeutic Landscape of GLP1 agonists.

The science, promise and clinical development of GLP-1 and GIP receptor agonists in obesity

Several multi-targeting agonists at GIPR, GLP-1R or GCGR, developed to maximize metabolic benefits with reduced side-effects, are in clinical trials to treat type 2 diabetes and obesity